newsfilter
← Latest News
Business Wire·

Forte Biosciences, Inc. Announces Results and Provides Update

Three clinical trial readouts for FB102 expected in 2026, including phase 2 in celiac disease and phase 1b in both vitiligo and alopecia areata Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a